Payment overview · 2025
General Payments
$1,166.82
87 reported records · 16 companies
Healthcare provider profile · identity verified
Brannon A. Treece, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JONESBORO, AR · NPI 1588783666
Verified facts
What the public records show
CMS Open Payments records show Brannon A. Treece, MD received $1,166.82 in general payments during 2025 across 87 reported records.
PFIZER INC. accounted for 30.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $357.95 | 30.7% | 33 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $268.66 | 23.0% | 25 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $104.66 | 9.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.19 | 6.6% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.27 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.55 | 4.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.99 | 4.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.18 | 3.1% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.02 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.02 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.67 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.09 | 1.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.70 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.21 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.92 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,166.82 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $354.86 | 32 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $249.18 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $194.14 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.17 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $105.68 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $104.66 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.81 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.99 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.99 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.27 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| OSTEOCOOL RF ABLATION SYSTEM Normalized: osteocool rf ablation system |
Device | Medtronic, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $29.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $26.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.74 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $3.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 360 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 125 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
73 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
125 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
360 | 43 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 135 |
| Gabapentin | Gabapentin | 749 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 674 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 669 | 132 |
| Potassium Chloride | Potassium Chloride | 661 | 121 |
| Alprazolam | Alprazolam | 631 | 103 |
| Furosemide | Furosemide | 563 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 96 |
| Duloxetine Hcl | Duloxetine Hcl | 446 | 83 |
| Trazodone Hcl | Trazodone Hcl | 387 | 73 |
| Losartan Potassium | Losartan Potassium | 366 | 83 |
| Eliquis | Apixaban | 360 | 43 |
| Omeprazole | Omeprazole | 348 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 331 | 71 |
| Metformin Hcl | Metformin Hcl | 325 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 324 | 61 |
| Lisinopril | Lisinopril | 321 | 72 |
| Sertraline Hcl | Sertraline Hcl | 318 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 298 | 48 |
| Tramadol Hcl | Tramadol Hcl | 279 | 53 |
| Carvedilol | Carvedilol | 270 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 251 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 44 |
| Montelukast Sodium | Montelukast Sodium | 222 | 36 |
| Baclofen | Baclofen | 217 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 217 | 80 |
| Simvastatin | Simvastatin | 211 | 43 |
| Memantine Hcl | Memantine Hcl | 206 | 34 |
| Allopurinol | Allopurinol | 198 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 36 |
| Spironolactone | Spironolactone | 183 | 40 |
| Levetiracetam | Levetiracetam | 181 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 165 | 24 |
| Donepezil Hcl | Donepezil Hcl | 163 | 31 |
| Buspirone Hcl | Buspirone Hcl | 159 | 30 |
| Clonazepam | Clonazepam | 157 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 152 | 29 |
| Famotidine | Famotidine | 151 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 144 | 54 |
| Ezetimibe | Ezetimibe | 142 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 139 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 26 |
| Jardiance | Empagliflozin | 126 | 19 |
| Mounjaro | Tirzepatide | 125 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 124 | 28 |
| Mirtazapine | Mirtazapine | 123 | 23 |
| Pregabalin | Pregabalin | 119 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 117 | 17 |
| Terazosin Hcl | Terazosin Hcl | 115 | 23 |
| Lorazepam | Lorazepam | 113 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 20 |
| Lamotrigine | Lamotrigine | 110 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 16 |
| Nifedipine Er | Nifedipine | 106 | 18 |
| Januvia | Sitagliptin Phosphate | 104 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 34 |
| Glimepiride | Glimepiride | 96 | 18 |
| Atenolol | Atenolol | 94 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 16 |
| Prednisone | Prednisone | 90 | 33 |
| Alendronate Sodium | Alendronate Sodium | 89 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 18 |
| Primidone | Primidone | 84 | 13 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Finasteride | Finasteride | 83 | 14 |
| Meloxicam | Meloxicam | 83 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 18 |
| Estradiol | Estradiol | 80 | 17 |
| Entresto | Sacubitril/Valsartan | 78 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 12 |
| Glipizide | Glipizide | 74 | suppressed |
| Myrbetriq | Mirabegron | 73 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 32 |
| Nystatin | Nystatin | 69 | 33 |
| Cephalexin | Cephalexin | 68 | 37 |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | suppressed |
| Fluconazole | Fluconazole | 63 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 63 | 13 |
| Sucralfate | Sucralfate | 63 | 16 |
| Ranolazine Er | Ranolazine | 62 | 11 |
| Lovastatin | Lovastatin | 61 | 12 |
| Ozempic | Semaglutide | 61 | 14 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 22 |
| Latanoprost | Latanoprost | 58 | suppressed |
| Sotalol | Sotalol Hcl | 58 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 56 | 16 |
| Doxepin Hcl | Doxepin Hcl | 56 | suppressed |
| Topiramate | Topiramate | 56 | 11 |
| Promethazine Hcl | Promethazine Hcl | 55 | 11 |
| Lansoprazole | Lansoprazole | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 53 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Colchicine | Colchicine | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 52 | 28 |
| Celecoxib | Celecoxib | 51 | 11 |
| Diazepam | Diazepam | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Bumetanide | Bumetanide | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Linzess | Linaclotide | 47 | 14 |
| Olanzapine | Olanzapine | 47 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 45 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 27 |
| Temazepam | Temazepam | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 41 | 28 |
| Nyamyc | Nystatin | 41 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 39 | 26 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Methimazole | Methimazole | 36 | suppressed |
| Insulin Aspart | Insulin Aspart | 35 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 20 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 21 |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Nystop | Nystatin | 15 | 11 |
| Ajovy Syringe | Fremanezumab-Vfrm | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Vimpat | Lacosamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,166.82 · 87 records | PFIZER INC. | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, GEMTESA, GOMEKLI, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OSTEOCOOL RF ABLATION SYSTEM, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error